喹硫平与奋乃静治疗老年精神分裂症的临床疗效比较

目的:比较喹硫平和奋乃静治疗老年精神分裂症的疗效和安全性。方法:喹硫平组30例男性13例,女性17例,年龄(67±s10)a,BPRS评分(44±8)分]用喹硫平200～400mg·d-1,po,bid;奋乃静组30例男性14例,女性16例,年龄(64±7)a,BPRS评分(43±7)分]用奋乃静8～20mg·d-1,po,bid。临床疗效和不良反应以BPRS,TESS评分观察4wk。结果:喹硫平组总有效率为90%,奋乃静组为83%(P>0.05)。喹硫平组对兴奋躁动控制较好,与奋乃静组较高的锥体外系症状(23%)比较差异有显著意义(P<0.01),其他不良反应2组相仿,且程度较轻。结论:喹硫平与奋乃静疗效相似。喹硫平不良反应轻,病人耐受良好,适宜在老年病人中推广应用。

Clinical effects of quetiapine vs perphenazine in treatment of elderly schizophrenia

AIM: To compare the effectiveness and safety of quetiapine and perphenazine in the treatment of elderly schizophrenia. METHODS: Thirty patients ((M 13, F 17), age (67±s 10) a, BPRS scores (44±8)) were treated with quetiapine 200- 400 mg·d -1, po, bid, Thirty patients (M 14, F 16), age (64±7) a, BPRS scores (43±7)] treated with perphenazine 8-20 mg·d -1, po, bid. The clinical effects and adverse reactions were assessed by BPRS, TESS for 4 wk. RESULTS: The total effective rates of quetiapine group and perphenazine group were 90 % and 83 % respectively(P>0.05). The exciting and mania were controlled better in quetiapine group. There was a significant difference in control of extrapyramidal system symptoms between the two groups, higher in perphenazine group(P<0.01). The other adverse reactions were mild and similar in two groups. CONCLUSION: Quetiapine and perphenazine possess similar efficacy in the treatment of elder schizophrenia. Quetiapine shows well tolerance and less adverse reactions especially suitable for the elderly and worthy to be recommended.